Our SAC® (Sigma Anti-bonding Calcium Carbonate) and SG (Stealth Glucose) formula (YYM1) was recently tested in a preclinical laboratory study, examining its effects on tumor growth in a colorectal cancer model (Colo205). The findings demonstrate a measurable inhibitory effect, reinforcing its potential role in cellular health.
Key Findings:
31.4% Tumor Growth Reduction – Tumors in the SAC® and SG group (YYM1) were significantly smaller than in the control group, demonstrating a clear inhibitory effect.
No Toxicity, No Harmful Side Effects – The test subjects showed no treatment-related deaths or severe adverse effects, confirming the formula’s safety profile.
Tumor Growth Slowed After Day 11 – The data suggests SAC® and SG may disrupt tumor proliferation pathways, slowing its progression over time.
Weight Stability & Systemic Tolerance – While minor fluctuations in body weight were observed, overall health remained stable, indicating strong bioavailability and metabolic compatibility.
Considerations for Future Research
While these findings are promising, further studies are required to fully assess SAC® and SG’s long-term effects:
- Long-Term Effects – The study was conducted over a limited timeframe, and additional research is needed to assess long-term cellular and systemic responses.
- Mechanism of Action (MOA) & Biomarkers – Further studies will explore how SAC® and SG interact with molecular pathways that regulate abnormal cell growth.
- Dosing Optimization & Combination Therapy – Additional studies are needed to evaluate higher/lower dosing regimens and potential synergies with existing cancer treatments (chemotherapy/immunotherapy).
- Sample Size Consideration – With n=8 per group, larger studies are necessary for statistically robust conclusions.
What This Means for Human Health
The human body operates on a larger biological scale, but the fundamental cellular mechanisms regulating growth, repair, and immune function remain highly conserved. The ability of SAC® and SG to slow abnormal cellular activity suggests it may have broad applications for long-term cellular resilience and physiological balance. While further research is needed to determine precise dosage scaling, long-term effects, and human-specific responses, these findings provide an important scientific foundation for SAC® and SG’s role in supporting cellular health.
Conclusion
The results of the study is promising as it indicates that SAC® and SG exhibit anti-tumor efficacy, reducing tumor growth by 31.4% compared to the control. While it does not eliminate tumors entirely, these findings support further research to determine its full potential in clinical applications. These findings align with our mission—to develop cutting-edge, naturally derived solutions that work in sync with your body’s biology.
The information provided in this article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The preclinical study results discussed are based on laboratory research using a colorectal cancer model (Colo205) and do not constitute evidence of efficacy or safety in humans. The findings are preliminary and have not been evaluated by the U.S. Food and Drug Administration (FDA), Health Canada, or any other regulatory body. SAC-SG (YYM1) is not approved for the prevention, treatment, or cure of any disease, including cancer. Further clinical studies are required to validate these results and determine the safety, efficacy, and appropriate use of SAC-SG in humans. Always consult a qualified healthcare professional before starting any new treatment or making changes to your health regimen. The company and its affiliates are not liable for any actions taken based on the information provided in this article.
Research Partners
